RT Journal
A1 Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S
T1 Vardenafil for the treatment of raynaud phenomenon: A randomized, double-blind, placebo-controlled crossover study
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD August 13
VO 172
IS 15
SP 1182
OP 1184
DO 10.1001/archinternmed.2012.2271
UL http://dx.doi.org/10.1001/archinternmed.2012.2271
AB 
Raynaud phenomenon (RP) is common and occurs with severe symptoms, particularly in patients with connective tissue disease (CTD), in whom RP may lead to digital ulcerations and amputations.1- 2 Medical therapy in these patients remains unsatisfactory. Administration of phosphodiesterase type 5 (PDE5) inhibitors, which inhibit the degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, promote vasorelaxation and are a promising therapeutic approach. However, randomized controlled trials have yielded conflicting results.3 We previously had conducted an open-label study with vardenafil hydrochloride trihydrate in patients with RP as a proof of concept.4 Our objective was to confirm our findings in a double-blind, randomized, placebo-controlled trial.